Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group. Balar AV, et al. Among authors: abidoye oo. Lancet. 2017 Jan 7;389(10064):67-76. doi: 10.1016/S0140-6736(16)32455-2. Epub 2016 Dec 8. Lancet. 2017. PMID: 27939400 Free PMC article. Clinical Trial.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R. Rosenberg JE, et al. Lancet. 2016 May 7;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4. Epub 2016 Mar 4. Lancet. 2016. PMID: 26952546 Free PMC article. Clinical Trial.
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
Sattler M, Abidoye O, Salgia R. Sattler M, et al. ScientificWorldJournal. 2008 Sep 21;8:909-19. doi: 10.1100/tsw.2008.117. ScientificWorldJournal. 2008. PMID: 18836658 Free PMC article. Review.
Review of clinic trials: agents targeting c-Met.
Abidoye O, Murukurthy N, Salgia R. Abidoye O, et al. Rev Recent Clin Trials. 2007 May;2(2):143-7. doi: 10.2174/157488707780599357. Rev Recent Clin Trials. 2007. PMID: 18473999 Review.
MET as a target for treatment of chest tumors.
Cipriani NA, Abidoye OO, Vokes E, Salgia R. Cipriani NA, et al. Among authors: abidoye oo. Lung Cancer. 2009 Feb;63(2):169-79. doi: 10.1016/j.lungcan.2008.06.011. Epub 2008 Jul 30. Lung Cancer. 2009. PMID: 18672314 Free PMC article. Review.
Lung carcinoma in African Americans.
Abidoye O, Ferguson MK, Salgia R. Abidoye O, et al. Nat Clin Pract Oncol. 2007 Feb;4(2):118-29. doi: 10.1038/ncponc0718. Nat Clin Pract Oncol. 2007. PMID: 17259932 Review.
11 results